Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (ACTRN12625001006437) titled 'A Phase 1, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of intravenously infused IB409 in healthy adult participants' on Sept. 10.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Infensa Bioscience Pyt Ltd
Condition:
Myocardial Infarction
Myocardial Infarction
Cardiovascular - Coronary heart disease
Emergency medicine - Other emergency care
Intervention:
This is a study of safety, tolerabilit...